Stocklytics Platform
Asset logo for symbol GILD
Gilead Sciences
GILD71
$91.03arrow_drop_down1.18%-$1.08
S&P500
Asset logo for symbol GILD
GILD71

$91.03

arrow_drop_down1.18%
Key Stats
Open$91.86
Prev. Close$92.13
EPS0.09
Next Earnings DateApr 3, 2025
LOWHIGH
Day Range91.03
92.12
52 Week Range62.07
98.83
Ratios
EPS0.09
Fundamentals
Industry average yield2.72%
Last Dividend pay dateDec 30, 2024

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

GILD-
US Healthcare Sector-
US Market-
warning

GILD / Market

GILD lose to the US Market which returned -0.64% over the last twenty four hours.
warning

GILD / Healthcare Sector

GILD lose to the US Healthcare sector which returned 2.58% over the last twenty four hours.

Gilead Sciences (GILD) Statistics

Gilead Sciences Inc, also known as GILD, is a leading biotechnology company with a strong focus on research and development of innovative therapies in the fields of HIV, hepatitis, and other viral diseases. The company is known for its groundbreaking antiviral drugs, including the widely used HIV drugs Truvada and Atripla. Gilead Sciences Inc has a market capitalization of over $80 billion, making it one of the largest biotech companies in the world.
When it comes to valuation metrics, Gilead Sciences Inc has a price-to-earnings ratio (P/E) of 10.56, which indicates that the stock is currently undervalued compared to its earnings. The company also has a price-to-sales ratio (P/S) of 3.67, suggesting that investors are willing to pay a premium for its revenue. In terms of fundamentals, Gilead Sciences Inc has a strong balance sheet with a total debt of $27.2 billion and a gross profit of $24.7 billion. The company's profit margin stands at 43.89%, indicating that it is highly efficient in turning revenue into profit.
add Gilead Sciences  to watchlist

Keep an eye on Gilead Sciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How much debt does Gilead Sciences (GILD) have?

Gilead Sciences (GILD) has a total debt of $23.25B. The net debt, which accounts for cash and cash equivalents against the total debt, is $18.21B.
help

How has Gilead Sciences (GILD) stock's performance compared to its sector and the market over the past year?

Over the past year, Gilead Sciences (GILD) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 30.78%, Gilead Sciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 59.85%, it has fallen short of the market average. This comparison highlights Gilead Sciences 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Gilead Sciences (GILD) stock?

The PE (Price to Earnings) ratio of Gilead Sciences (GILD) is currently 1.01K. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of Gilead Sciences (GILD) stock?

The Earnings Per Share (EPS) for Gilead Sciences (GILD), calculated on a diluted basis, is $0.09. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Gilead Sciences (GILD) stock?

The operating margin for Gilead Sciences (GILD) is 41.96%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Gilead Sciences (GILD) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Gilead Sciences (GILD) is $10.48B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

Take Your Investments to a Whole New Level